<p>The MPN Hub was pleased to speak with John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, US. We asked, What is on the horizon for the treatment of myelofibrosis-related anemia?&nbsp;</p><p>&nbsp;</p><p>In this interview, Mascarenhas explores the emerging strategies for myelofibrosis-associated anemia, with a focus on agents targeting the TGF-β superfamily members and hepcidin modulation, including luspatercept, elritercept, and DISC-0974. Mascarenhas notes that whether these approaches are most effective as single agents, in combination, or at specific stages of anemia progression remains to be determined.&nbsp;</p><br><p>This educational resource is independently supported by GSK. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.&nbsp;</p><hr><p style='color:grey; font-size:0.75em;'> Hosted on Acast. See <a style='color:grey;' target='_blank' rel='noopener noreferrer' href='https://acast.com/privacy'>acast.com/privacy</a> for more information.</p>